Trial Profile
A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 26 May 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2010 Additional lead trial centres identified as reported by ClinicalTrials.gov.